Effectiveness of 0.15% hylan A eye drops in ameliorating symptoms of severe dry eye patients in Saudi Arabia

Abstract

PURPOSE:

The aim of the HYLAN A study was to investigate if symptoms and/or signs of patients suffering from severe dry eye disease (DED) in Saudi Arabia can be improved by substituting individually optimized artificial tear therapy by high molecular weight hyaluronan (HMWHA) eye drops.

METHODS:

The HYLAN M study, a multicenter prospective randomized open-label study, was performed in 11 centers in eight countries. Patients suffering from severe DED were electronically randomized in two parallel arms. patients with symptoms of at least ocular surface disease index (OSDI) 33 and corneal fluorescein staining (CFS) of at least Oxford grade 3 were included . The patients in the control group continued with their individual optimized therapy as by the time of inclusion. The patients in the hylan A group replaced their individual lubricant eye drops by preservative-free eye drops containing 0.15% hylan A. The total OSDI scores as well as the OSDI subscores for pain and for visual disturbances of each patient at baseline, at 4 weeks, and at 8 weeks of treatment was used to analyse the improvement of symptoms. We focus and report the results obtained at the two study centers in Riyadh ,Saudi Arabia (King Khaled Eye Specialist Hospital and Riyadh Military Hospital).

RESULTS:

A total of 13 patients were included in the study. The majority of the study participants were middle aged (40-65 years). Overall, female patients accounted for 76.9% of all study participants. At the initiation of the study, both hylan A and control groups had relatively similar total OSDI scores together with pain and vision subscores. At 4-week follow-up, both groups demonstrated a noticeable decrease in all study variables. Nevertheless, the OSDI scores improved significantly in the group of patients treated with hylan A eye drops at 8 weeks, whereas the scores increased in the control group.

CONCLUSION:

Saudi Arabia has a very high prevalence of patients with severe dry eye disease. Ethnicity, climate, and a high incidence of diabetes mellitus may contribute to this situation. Lubricant eye drops frequently do not provide adequate relief from ocular pain and instable vision in severe chronic ocular surface disease. High molecular weight hyaluronan (HMWHA) eye drops provide superior relief of symptoms of patients suffering from severe DED. This includes ocular pain as well as unstable vision.

INTRODUCTION

Discomfort and pain at the surface of the eye, with or without signs of corneoconjunctival tissue damage, are the dominant symptoms of dry eye disease (DED) and other conditions affecting the ocular surface. Studies in the USA, Spain, and France found a prevalence of 14% to 39%, whereas studies in Asia showed a prevalence of 20% to 52% for symptomatic DED.[1] For the population in Saudi Arabia, a DED prevalence of 32% to 93% has been reported.[2,3,4,5,6,7] A high percentage of dry eye patients in Saudi Arabia reported severe symptoms.[4,5,8] Moreover, among the patients with DED, there seems to be a very high percentage simultaneously suffering from diabetes mellitus (DM).[4] DED has a significant impact on work productivity, in particular on Saudi office workers.[9] Tear replacement with lubricating, hydrating eye drops which provide palliative relief from symptoms are the mainstay for long-term treatment of DED. This type of treatment is not targeting the underlying pathophysiology of the disease.[10] Particularly, severe DED associated with chronic inflammation requires a personalized treatment, prescribing the artificial tears which provide the best symptom relief for the individual patient.[11] Most lubricant eye drop formulations were developed in the USA, Europe, or Japan, and were never subject to a controlled clinical study of dry eye patients of Arab ethnicity and under the conditions of the climate in Saudi Arabia. For the first time, the HYLAN M study on patients with severe DED compared data from two study centers in Riyadh, Saudi Arabia, with those from nine study centers in Europe.[12] Tear substitutes containing 0.15% hylan A were compared with other lubricant eye drops which had been used by the patients as individual best treatment by the time of their inclusion into the study. The Asia Dry Eye Society recently proposed to use subjective severity of dry eye as a marker for therapeutic efficacy.[13] Various questionnaires are available for the assessment of dry eye symptoms.[14] In our study, we used the Ocular Surface Disease Index (OSDI) questionnaire.[15] According to Miller et al., an OSDI score up to 12 is considered as normal eye, a score from 13 to 22 as mild, from 23 to 32 as moderate, and 33 or more as severe dry eye.[16]

METHODS

Study design

The HYLAN M study, a multicenter prospective randomized open-label study, was performed in 11 centers in eight countries. The study adhered to the Declaration of Helsinki, was approved by the Ethics Committees of each center, and registered under the number CIV-16-06-015964 on the EUDAMED database of the European Commission. Patients suffering from severe DED were electronically randomized in two parallel arms. The patients in the control group continued with their individual optimized therapy as by the time of inclusion. The patients in the hylan A group replaced their individual lubricant eye drops by preservative-free eye drops containing 0.15% hylan A dissolved in isotonic saline solution buffered with 1.20 mmol/L phosphate (Comfort Shield^® eye drops; i.com medical, Munich, Germany). Hylan A is a very high-molecular weight hyaluronic acid (HA).[17] The intrinsic viscosity of hylan A in our study was 2.9 m≥/kg. Further details of the study design have been published elsewhere.[12] Here, we report on the results obtained at the two study centers located in Riyadh, Saudi Arabia.

Participants

Inclusion criteria included all patients over the age of 18 years known to present with DED of any etiology managed with dry eye regimen that have not been altered for at least 2 months. The primary criteria for severe DED according to Baudouin et al., i.e., OSDI score 33 or more in combination with corneal fluorescein staining (CFS) Oxford Grade 3 or more, were used for the study.[18,19] The eyes with the higher CFS score were defined as study eyes. Patients were excluded if they participated in any other clinical trial, suffered from eye diseases other than dry eye, had ocular surgery <3 months prior to study inclusion, were using punctual plugs, or had masquerading conditions, as identified by Karpecki.[20]

Efficacy assessment

The OSDI questionnaire was used for the assessment of therapeutic efficacy.[15] The patients answered the OSDI questions by the time of inclusion (baseline), after 4 weeks, and after 8 weeks. The difference between OSDI scores at week 8 and at baseline was used as the endpoint. To further analyze the improvement of symptoms, OSDI subscores for questions related to ocular pain and discomfort, OSDI_pain (OSDI questions 1–3), and OSDI questions related to stability of vision, OSDI_vision(OSDI questions 4–9), were separately calculated according to the following formulas:

n = number of questions answered (3 and 6, at most, for the pain and vision subscore, respectively).

Data analysis

Descriptive statistics of the patients were presented using frequency and percentage distribution. The independent t-test was used to test for the mean difference between the groups at baseline, after 4 weeks, and after 8 weeks. No assumptions of the independent t-test were violated.

The repeated measures analysis of variance with sphericity assumed was then used to examine the trend of OSDI scores and to test for the difference in OSDI scores from baseline, to 4 weeks, and to 8 weeks. All assumptions of the repeated-measures ANOVA were also tested and none was violated.

The Mauchly’s test of sphericity was used to test for the assumption of sphericity. The results indicated that the assumption of sphericity was not violated in the OSDI score repeated measures, OSDI_pain, and OSDI_vision, χ² (2) = 1.44, P = 0.487, χ² (2) = 0.72, P = 0.698, and χ² (2) = 2.70, P = 0.26, respectively.

RESULTS

The majority of the study participants were middle aged (40–65 years). Overall, female patients accounted for 76.9% of all study participants. The mean age ± standard deviation (SD) for the hylan A and control groups were 39.7% (±11.1) and 46.7% (±11.0), respectively. The sociodemographic data for all patients are summarized in Table 1.

Table 1.

Sociodemographic data of study participants

Characteristics	Hylan A group (n=6), n (%)	Control group (n=7), n (%)
Age (years)
<40	2 (33.3)	1 (14.3)
40-65	4 (66.7)	6 (85.7)
Gender
Female	5 (83.3)	5 (71.4)
Male	1 (16.7)	2 (28.6)

Table 2 provides a complete summary of the OSDI scores as well as the OSDI subscores for pain and for visual disturbances of each patient at baseline, at 4 weeks, and at 8 weeks of treatment. At the initiation of the study, both hylan A and control groups had relatively similar total OSDI scores together with pain and vision subscores ranging between 40 and 60. At 4-week follow-up, both groups demonstrated a noticeable decrease in all study variables. Nevertheless, the OSDI scores improved significantly in the group of patients treated with hylan A eye drops at 8 weeks, whereas the scores increased in the control group reflecting the worsening of DED symptoms, as demonstrated in Figure 1.

Table 2.

Total Ocular Surface Disease Index scores as well as Ocular Surface Disease Index pain and Ocular Surface Disease Index vision subscores for hylan A and control groups

Treatment	n	Mean (±SD)
		Baseline	Week 4	Week 8
Total OSDI score
Hylan A group	6	62.3 (18.6)	36.9 (31.7)	26.5 (20.3)
Control group	7	63.0 (20.3)	49.7 (15.7)	65.9 (12.6)
OSDI pain
Hylan A group	6	59.7 (25.5)	37.5 (33.6)	30.6 (23.4)
Control group	7	59.5 (29.8)	50.0 (29.7)	59.5 (16.3)
OSDI vision
Hylan A group	6	50.0 (19.0)	22.2 (29.1)	13.9 (13.4)
Control group	7	41.1 (24.2)	35.1 (15.6)	46.4 (14.3)

OSDI: Ocular Surface Disease Index, SD: Standard deviation

Figure 1.

(a) Ocular Surface Disease Index score trend by time point, (b) Ocular Surface Disease Index pain trend by time point, (c) Ocular Surface Disease Index vision trend by time point

Table 3 presents the results of the repeated-measures ANOVA testing which showed that the total OSDI score was statistically significantly different between time points for the hylan A group and the control group (F [2, 10] = 5.123, P < 0.05) and (F [2, 12] = 4.72, P < 0.05), respectively. The results showed that while the total OSDI scores reduced for the hylan A group from baseline (mean = 62.3, SD = 18.4) to week 4 (mean = 36.9, SD = 31.7) and to week 8 (mean = 26.5, SD = 20.3), respectively, the total OSDI scores for the control group decreased from baseline (mean = 63.0, SD = 20.3) to week 4 (mean = 49.7, SD = 15.7) but increased significantly at week 8 (mean = 65.9, SD = 12.6).

Table 3.

Analysis of variance test results for total Ocular Surface Disease Index, Ocular Surface Disease Index pain, and Ocular Surface Disease Index vision for hylan A and control groups

Treatment	Source	Type III sum of squares	df	Mean square	F	P
Hylan A group	OSDI score	4089.8	2	2044.9	5.123	0.029
	Error (OSDI score)	3991.9	10	399.2
Control	OSDI score	1033.9	2	517.0	4.72	0.031
	Error (OSDI score)	1314.4	12	109.5
Hylan A group	OSDI pain	2785.5	2	1392.7	2.317	0.149
	Error (OSDI pain)	6010.8	10	601.1
Control	OSDI pain	423.3	2	211.6	0.753	0.492
	Error (OSDI pain)	3373.0	12	281.1
Hylan A group	OSDI vision	4290.1	2	2145.1	5.543	0.024
	Error (OSDI vision)	3869.6	10	387.0
Control	OSDI vision	448.1	2	224.0	0.917	0.426
	Error (OSDI vision)	2931.5	12	244.3

OSDI: Ocular Surface Disease Index

Regarding OSDI pain scores, the results showed that there was no statistically significant difference between the study time points for the hylan A group and the control group (F [2, 10] = 2.317, P = 0.149) and (F [2, 12] = 0.753, P ≤ 0.492), respectively. Results showed that OSDI pain mean reduced for the hylan A group from baseline (mean = 59.7, SD = 25.5) to week 4 (mean = 37.5, SD = 33.6) and to week 8 (mean = 30.6, SD = 23.4), respectively, while OSDI pain scores reduced for the control from baseline (mean = 59.5, SD = 29.8) to week 4 (mean = 50.0, SD = 29.7) and increased at week 8 (mean = 59.5, SD = 16.3). However, the results were not sufficient to conclude a significant reduction in pain at the different time points for both groups.

OSDI vision results demonstrated a statistically significant difference between time points for the hylan A group but not for the control group (F [2, 10] = 5.543, P < 0.05) and (F [2, 12] = 0.917, P ≤ 0.426), respectively. Post hoc analysis showed a statistically significant reduction in OSDI vision scores from (mean = 50, SD = 19) at baseline to (mean = 22.2, SD = 19.1) at 4 weeks to (mean = 13.9, SD = 13.3) at 8 weeks for the hylan A group but there was no significant reduction for the control group.

The independent t-test to compare both study groups’ total OSDI scores at baseline [Table 4] showed no statistically significant difference (t[11] = ‒0.06, P = 0.955); however, this score was statistically different after 8 weeks (t[11] = ‒4.27, P < 0.01]. Similarly, the OSDI pain scores for both groups were not different at baseline (t[11] = 0.01, P = 0.990), but they were statistically significantly different after 8 weeks of treatment (t[11] =‒2.63, P < 0.05). Likewise, the OSDI vision scores for hylan A and control groups were not significantly different at baseline (t[11] = 0.73, P = 0.481); yet, a significant difference was observed after 8 weeks of treatment (t[11] = ‒4.21, P < 0.01). The change of the OSDI scores and subscores from the baseline to the 8 weeks visit in the hylan A group as compared to the control group is visualized in Figure 2.

Table 4.

Student’s t-test results for hylan A and control groups at baseline and 8-week follow-up

	t	df	P	Mean difference	SE difference	95% CI
						Lower	Upper
Baseline OSDI score	−0.06	11	0.955	−0.63	10.87	−24.57	23.30
Week 8 OSDI score	−4.27	11	0.001	−39.40	9.23	−59.72	−19.08
Baseline OSDI pain	0.01	11	0.990	0.20	15.55	−34.02	34.42
Week 8 OSDI pain	−2.63	11	0.023	−28.97	11.02	−53.23	−4.71
Baseline OSDI vision	0.73	11	0.481	8.93	12.24	−18.02	35.88
Week 8 OSDI vision	−4.21	11	0.001	−32.54	7.73	−49.54	−15.53

CI: Confidence interval, SE: Standard error, OSDI: Ocular Surface Disease Index

Figure 2.

Change of the Ocular Surface Disease Index scores and subscores from baseline to 8 weeks in the hylan A group as compared to the control group

These results collectively demonstrate the efficacy of hylan A in reducing DED symptoms evidenced by a significant reduction in total OSDI scores. In addition, hylan A eye drops were likely to improve vision-related complaints, and to a lesser extent, pain-related symptoms in patients with DED.

DISCUSSION

Disturbed immunoregulation involving chronic inflammation is currently considered the characteristics of severe DED.[21] High-molecular weight HA is known to stabilize the epithelial barrier, suppress pain, and exercise immunosuppressive effects.[22,23,24] The Asia Dry Eye Society recently speculated that neuropathic components may determine the severity of dry eye symptoms.[13] Patients suffering from neuropathic pain have been reported to respond poorly to the treatment with lubricant eye drops.[25,26] Within the HYLAN M study, four of the participating centers had submitted images of the subbasal corneal nerve plexus taken by in vivo confocal microscopy at baseline and after 8 weeks of treatment with 0.15% hylan A eye drops. Significant nerve growth indicating the recovery of compromised corneal nerves under the treatment with 0.15% hylan A eye drops was found.[27] It is, therefore, hypothesized that the significant improvement of symptoms observed in the current study is at least partly due to the recovery of corneal nerves. Nerves provide essential support to the corneal epithelium.[28,29,30,31,32,33,34,35,36,37] 0.15% hylan A eye drops seem to contribute to regaining ocular surface homeostasis in eyes with chronic inflammation, although it needs to be emphasized that the observed improvement of symptoms has only been investigated in a small number of eyes.

Saudi Arabia is among the countries with the highest prevalence of DM.[38] DM is associated with progressive damage to corneal nerves and consequently epithelial cells, resulting in an increased risk for DED, corneal erosion, persistent epithelial defects, and eventually sight-threatening corneal ulcers.[39,40,41,42,43,44,45] About 50% of diabetic patients develop corneal neuropathy.[39,46,47,48,49] Corneal neuropathy is underrated due to the initial absence of ocular discomfort and pain.[49,50,51,52] The evidence that 0.15% hylan A eye drops support corneal nerve regeneration allows the assumption that these eye drops will offer a preventive therapy against the development and progression of diabetic keratopathy.[27] Other instances where 0.15% hylan A eye drops are likely to support the healing process of the ocular surface are ocular surgery, refractive surgery, corneal cross-linking, chemical burns, ocular trauma, keratoconus, or simply compromised corneal nerves due to aging.[53,54,55,56,57,58]

CONCLUSION

It has been shown that 0.15% hylan A eye drops provide superior relief of symptoms of patients suffering from severe DED. This includes ocular pain as well as unstable vision. 0.15% hylan A eye drops seem to simultaneously address the various and complex pathomechanisms of ocular surface disease, and in particular downregulate inflammation and provide trophic support to the corneal nerves. After any kind of ocular surgery, 0.15% hylan A eye drops may serve to ameliorate ocular discomfort and support the recovery of damaged nerves. 0.15% hylan A eye drops offer a therapeutic option for preventing and treating ocular surface disease, in particular conditions associated with corneal nerve damage like diabetic keratopathy.

Financial support and sponsorship

The HYLAN M study received unrestricted funding from i.com medical GmbH, Munich, Germany.

Conflicts of interest

Dr. Wolfgang G.K. Müller-Lierheim, the study director, is the CEO of the company i.com medical GmbH, Munich, Germany. The remaining authors declare no conflicts of interest.